Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: Yahoo! Finance
Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was generally well-tolerated with dose-dependent increases in tissue frataxin levels, reinforcing therapeutic potential Biologics License Application (“BLA”) submission targeted for 2H 2025; discussions initiated with Food and Drug Administration (“FDA”) on potential to pursue accelerated approval pathway Successful $161.8 million financing strengthens cash, cash equivalents, and marketable securities to $239 million as of March 31, 2024, extending projected cash runway into 2026 BALA CYNWYD, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2024 operating and financial results. “We have started 2024 off strong, achieving critical milestones that support late-stage advancement of our nomlabofusp clinical program. Positive Phas
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics Reports First Quarter 2024 Operating and Financial ResultsGlobeNewswire
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $25.00 price target on the stock.MarketBeat
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $25.00 price target on the stock.MarketBeat
LRMR
Earnings
- 3/14/24 - Miss
LRMR
Sec Filings
- 5/9/24 - Form S-3
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- LRMR's page on the SEC website